Figure 2.

ProAgio depletes CAPaSC by targeting integrin α_Vβ₃and resorbs tumor collagen. (A and B) Mean tumor volume of (A) subcutaneous xenograft of Panc1 with (solid lines) or without (dotted lines) co-implantation of PaSC and mean tumor weight (B) of Panc1 subcutaneous xenograft with or without co-implantation of PaSC upon treatment with vehicle (black lines in panel A, grey dots in panel B) or 10 mg/kg ProAgio (12 daily doses, red lines in panel A, red dots in panel B) (n = 6). (C and E) Representative images of immunofluorescence staining of α-SMA (red) (C) and Masson trichrome (blue) staining for collagen (E). (D and F) Quantitative analyses of immunofluorescence staining of α-SMA (D) and Masson trichrome (F) staining in tumor sections of Panc1 xenograft (with or without PaSC co-implantation) mice treated with vehicle or 10 mg/kg ProAgio. (G and I) Representative images of immunofluorescence staining of Ki67 (G, red) and CD31 (I, red). (H and J) Quantitative analyses of immunofluorescence staining of Ki67 (H) and quantification of mean vessel density, branch points, and vessel length based on CD31 staining (J) in tumor sections of Panc1 xenograft (with or without PaSC co-implantation) mice treated with vehicle or ProAgio. Quantification of Ki67 staining is presented as the percentage of Ki67⁺ nuclei per view field (upper 3 panels, with PaSC co-implantation; bottom 3 panels, without PaSC co-implantation). (C, G, and I) Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (A and B) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. n.s., denotes not significant.